Asfotase alfa regulatory update

FDA approved Strensiq asfotase alfa from Alexion to treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP) and granted the company a Priority Review voucher through the agency’s rare pediatric disease Priority Review voucher program. Alexion launched Strensiq in the U.S. and set an average annual U.S. price of $285,000, with weight-based dosing and other factors taken into account. ...